Tofacitinib for Inflammatory Eye Disease
| Status: | Recruiting |
|---|---|
| Conditions: | Cervical Cancer, Ocular, Ocular, Ocular |
| Therapuetic Areas: | Oncology, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/17/2019 |
| Start Date: | January 22, 2019 |
| End Date: | September 2020 |
| Contact: | Feigl |
| Email: | laceyfeigl@wustl.edu |
| Phone: | 3147474179 |
Tofacitinib for the Treatment of Inflammatory Eye Disease
Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic,
auto-immune process that leads to vision loss. While steroids are effective in the short
term, the side-effect profile of chronic steroid use necessitates the identification of
effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the
signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate
whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.
auto-immune process that leads to vision loss. While steroids are effective in the short
term, the side-effect profile of chronic steroid use necessitates the identification of
effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the
signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate
whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.
Inclusion Criteria:
- diagnosis of uveitis
- a clinical response to steroids
- active disease requiring at least 10mg of prednisone daily (or steroid equivalent)
Exclusion Criteria:
- suspected or confirmed ocular infection
- chronic or recurring infections, such as HIV
- renal insufficiency that would preclude safe administration of tofacitinib
We found this trial at
1
site
Click here to add this to my saved trials
